Danielle Charpentier

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.7K citations · Full text

Chemotherapy Versus Placebo, Breast Oncology, Oncology +7

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

Cora N. Sternberg, Iwona Skoneczna, J. Martijn Kerst et al. · The Lancet Oncology · 2014 · 381 citations

Radical Cystectomy, Urology, Surgical Oncology +7

Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type <i>K-RAS</i> Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial

Lillian L. Siu, Jeremy Shapiro, Derek J. Jonker et al. · Journal of Clinical Oncology · 2013 · 125 citations · Full text

Health-Related Quality of Life in Patients With Advanced Colorectal Cancer Treated With Cetuximab: Overall and <i>KRAS</i>-Specific Results of the NCIC CTG and AGITG CO.17 Trial

Heather‐Jane Au, Christos S. Karapetis, Chris J. O’Callaghan et al. · Journal of Clinical Oncology · 2009 · 113 citations · Full text

Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG)

Maureen Trudeau, Michael Crump, Danielle Charpentier et al. · Annals of Oncology · 2006 · 113 citations · Full text

National Cancer Institute, Metastatic Breast Cancer, Breast Oncology +8